Endolytix Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$9.3M
- Investors
-
3
Endolytix General Information
Description
Developer of novel therapeutics designed to cure antibiotic infections. The company provides therapies that are effective in killing pathogenic bacteria, including multidrug-resistant bacteria, enabling the healthcare industry to address the most resistant antibiotic infections that are difficult to access and treat.
Contact Information
Website
www.endolytx.bioCorporate Office
- 48 Dunham Ridge
- Suite 5850
- Beverly, MA 01915
- United States
Corporate Office
- 48 Dunham Ridge
- Suite 5850
- Beverly, MA 01915
- United States
Endolytix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 07-Aug-2024 | $9.3M | Completed | Generating Revenue | ||
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. Early Stage VC | 26-Mar-2021 | $12M | $12M | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Endolytix Patents
Endolytix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024020533-A1 | Immunogenic compositions for treating or preventing actinomycetia infections | Inactive | 22-Jul-2022 | ||
| WO-2024020543-A2 | Kits and methods for diagnosing and treating actinomycetia infections | Inactive | 22-Jul-2022 | ||
| WO-2024020543-A3 | Kits and methods for diagnosing and treating actinomycetia infections | Inactive | 22-Jul-2022 | ||
| AU-2023265152-A1 | Compositions and methods for the treatment of actinomycetia infections | Pending | 06-May-2022 | ||
| EP-4518840-A2 | Compositions and methods for the treatment of actinomycetia infections | Inactive | 06-May-2022 | A61K38/47 |
Endolytix Signals
Endolytix Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kineticos Life Sciences Management | Venture Capital | Minority | ||
| Morningside Group | Venture Capital | Minority | ||
| InnoVentures Lab | Accelerator/Incubator |
Endolytix FAQs
-
When was Endolytix founded?
Endolytix was founded in 2020.
-
Where is Endolytix headquartered?
Endolytix is headquartered in Beverly, MA.
-
What is the size of Endolytix?
Endolytix has 16 total employees.
-
What industry is Endolytix in?
Endolytix’s primary industry is Drug Discovery.
-
Is Endolytix a private or public company?
Endolytix is a Private company.
-
What is Endolytix’s current revenue?
The current revenue for Endolytix is .
-
How much funding has Endolytix raised over time?
Endolytix has raised $21.3M.
-
Who are Endolytix’s investors?
Kineticos Life Sciences Management, Morningside Group, and InnoVentures Lab have invested in Endolytix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process